Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 750

1.

Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study.

Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Cohen DJ, Steg PG, Cannon CP, Apruzzese PK, D'Agostino RB Sr, Massaro JM, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators..

JAMA Cardiol. 2017 Mar 15. doi: 10.1001/jamacardio.2017.0063. [Epub ahead of print]

PMID:
28297015
2.

Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial.

Giugliano RP, Wiviott SD, Blazing MA, De Ferrari GM, Park JG, Murphy SA, White JA, Tershakovec AM, Cannon CP, Braunwald E.

JAMA Cardiol. 2017 Mar 14. doi: 10.1001/jamacardio.2017.0083. [Epub ahead of print]

PMID:
28291866
3.

Serial Measurement of High Sensitivity Troponin I and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus in the EXAMINE Trial.

Cavender MA, White WB, Jarolim P, Bakris GL, Cushman WC, Kupfer S, Gao Q, Mehta CR, Zannad F, Cannon CP, Morrow DA.

Circulation. 2017 Feb 28. pii: CIRCULATIONAHA.116.024632. doi: 10.1161/CIRCULATIONAHA.116.024632. [Epub ahead of print]

PMID:
28246236
4.

Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention.

Bohula EA, Morrow DA, Giugliano RP, Blazing MA, He P, Park JG, Murphy SA, White JA, Kesaniemi YA, Pedersen TR, Brady AJ, Mitchel Y, Cannon CP, Braunwald E.

J Am Coll Cardiol. 2017 Feb 28;69(8):911-921. doi: 10.1016/j.jacc.2016.11.070.

PMID:
28231942
5.

Lipid-Lowering Efficacy and Safety of Alirocumab in Patients with or without Diabetes: A Sub-Analysis of ODYSSEY COMBO II.

Leiter LA, Zamorano JL, Bujas-Bobanovic M, Louie MJ, Lecorps G, Cannon CP, Handelsman Y.

Diabetes Obes Metab. 2017 Feb 16. doi: 10.1111/dom.12909. [Epub ahead of print]

PMID:
28206704
6.

Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial.

Bergmark BA, Cannon CP, White WB, Jarolim P, Liu Y, Bonaca MP, Zannad F, Morrow DA.

Diabetes Obes Metab. 2017 Feb 14. doi: 10.1111/dom.12905. [Epub ahead of print]

PMID:
28195387
7.

Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial.

Eisen A, Cannon CP, Braunwald E, Steen DL, Zhou J, Goodrich EL, Im K, Dalby AJ, Spinar J, Daga S, Lukas MA, O'Donoghue ML.

J Am Heart Assoc. 2017 Jan 11;6(1). pii: e004332. doi: 10.1161/JAHA.116.004332.

8.

Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.

Heller SR, Bergenstal RM, White WB, Kupfer S, Bakris GL, Cushman WC, Mehta CR, Nissen SE, Wilson CA, Zannad F, Liu Y, Gourlie NM, Cannon CP; EXAMINE Investigators..

Diabetes Obes Metab. 2017 Jan 6. doi: 10.1111/dom.12871. [Epub ahead of print]

PMID:
28058763
9.

Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication.

Mancia G, Cannon CP, Tikkanen I, Zeller C, Ley L, Woerle HJ, Broedl UC, Johansen OE.

Hypertension. 2016 Dec;68(6):1355-1364.

PMID:
27977392
10.

Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome.

Lindholm D, James SK, Bertilsson M, Becker RC, Cannon CP, Giannitsis E, Harrington RA, Himmelmann A, Kontny F, Siegbahn A, Steg PG, Storey RF, Velders MA, Weaver WD, Wallentin L; PLATO Investigators..

Clin Chem. 2017 Feb;63(2):573-584. doi: 10.1373/clinchem.2016.261271.

PMID:
27932413
11.

On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT).

Blazing MA, Giugliano RP, de Lemos JA, Cannon CP, Tonkin A, Ballantyne CM, Lewis BS, Musliner TA, Tershakovec AM, Lokhnygina Y, White JA, Reist C, McCagg A, Braunwald E.

Am Heart J. 2016 Dec;182:89-96. doi: 10.1016/j.ahj.2016.09.004.

PMID:
27914504
12.

Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease.

Hagström E, Held C, Stewart RA, Aylward PE, Budaj A, Cannon CP, Koenig W, Krug-Gourley S, Mohler ER 3rd, Steg PG, Tarka E, Östlund O, White HD, Siegbahn A, Wallentin L; STABILITY Investigators..

Clin Chem. 2017 Jan;63(1):325-333. doi: 10.1373/clinchem.2016.260570.

PMID:
27811204
13.

Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update.

Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, Cannon CP, Tanguay JF, Granger CB, Mauri L, Holmes DR, Gibson CM, Faxon DP.

Circ Cardiovasc Interv. 2016 Nov;9(11). pii: e004395.

PMID:
27803042
14.

Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.

Cannon CP, Gropper S, Bhatt DL, Ellis SG, Kimura T, Lip GY, Steg PG, Ten Berg JM, Manassie J, Kreuzer J, Blatchford J, Massaro JM, Brueckmann M, Ferreiros Ripoll E, Oldgren J, Hohnloser SH; RE-DUAL PCI Steering Committee and Investigators..

Clin Cardiol. 2016 Oct;39(10):555-564. doi: 10.1002/clc.22572.

15.

Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control.

Ray KK, Ginsberg HN, Davidson MH, Pordy R, Bessac L, Minini P, Eckel RH, Cannon CP.

Circulation. 2016 Dec 13;134(24):1931-1943.

16.

Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia.

Kastelein JJ, Kereiakes DJ, Cannon CP, Bays HE, Minini P, Lee LV, Maroni J, Farnier M.

Coron Artery Dis. 2016 Oct 12. [Epub ahead of print]

PMID:
27740972
17.

The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial.

Eisen A, Cannon CP, Blazing MA, Bohula EA, Park JG, Murphy SA, White JA, Giugliano RP, Braunwald E; IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators..

Eur Heart J. 2016 Dec 21;37(48):3576-3584. doi: 10.1093/eurheartj/ehw377.

PMID:
27569841
18.

Reply: High Risk of Gastrointestinal Bleeding on Dual Antiplatelet Treatment.

Vaduganathan M, Bhatt DL, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Cannon CP; COGENT Investigators..

J Am Coll Cardiol. 2016 Aug 30;68(9):981-2. doi: 10.1016/j.jacc.2016.06.008. No abstract available.

PMID:
27561775
19.

Acute myocardial infarction.

Reed GW, Rossi JE, Cannon CP.

Lancet. 2017 Jan 14;389(10065):197-210. doi: 10.1016/S0140-6736(16)30677-8. Review. Erratum in: Lancet. 2017 Jan 14;389(10065):156.

PMID:
27502078
20.

Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.

White WB, Wilson CA, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Heller SK, Mehta CR, Nissen SE, Zannad F, Kupfer S; EXAMINE Investigators..

Hypertension. 2016 Sep;68(3):606-13. doi: 10.1161/HYPERTENSIONAHA.116.07797.

PMID:
27480840

Supplemental Content

Loading ...
Support Center